<DOC>
	<DOCNO>NCT02383888</DOCNO>
	<brief_summary>To investigate safety , tolerability pharmacokinetics BI 425809 tablet healthy Chinese Japanese male subject follow administration single rise oral dos explore pharmacokinetics ( PK ) include dose proportionality BI 425809 single dose product .</brief_summary>
	<brief_title>Single Rising Dose Trial BI 425809 Healthy Japanese Chinese Male Subjects</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : Healthy male subject accord investigator 's assessment , base complete medical history include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory test Age 20 45 year ( incl . ) BMI 18.5 25 kg/m2 ( incl . ) Signed date write informed consent prior admission study accordance GCP local legislation Chinese ethnicity , Japanese ethnicity accord follow criterion : Chinese : ethnic Chinese , born China ethnic Chinese born outside China , descendent 4 ethnic Chinese grandparent born China Japanese : born Japan , live outside Japan &lt; 10 year , parent grandparent born Japan Exclusion criterion : Any find medical examination ( include BP , PR ECG ) deviate normal judge clinically relevant investigator Repeated measurement systolic blood pressure &lt; 90 &gt; 140 mmHg , diastolic blood pressure &lt; 50 &gt; 90 mmHg , PR &lt; 50 &gt; 90 Any laboratory value outside reference range investigator considers clinical relevance Any evidence concomitant disease judge clinically relevant investigator Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract could interfere kinetics trial medication Diseases central nervous system ( include limit kind seizure stroke ) , neurological disorder psychiatric disorder History relevant orthostatic hypotension , faint spell , blackout Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy trial medication excipients ) Intake drug long halflife ( 24 h ) within 30 day less 10 half life respective drug prior administration trial medication Within 10 day prior administration trial medication , use drug might reasonably influence result trial might prolong QT/QTc interval Participation another trial investigational drug administration within 60 day prior administration trial medication Smoker ( 10 cigarette 3 cigar 3 pipe per day ) Inability refrain smoke specify trial day Alcohol abuse ( consumption 20 g per day ) Drug abuse positive drug screen Blood donation 100 mL within 30 day prior administration trial medication intend donation trial Intention perform excessive physical activity within one week prior administration trial medication trial Inability comply dietary regimen trial site At screening , mark baseline prolongation QT/QTcF interval ( repeat demonstration QTcF interval great 450 m relevant ECG find A history additional risk factor Torsades de Pointes ( heart failure , hypokalemia , family history Long QT Syndrome ) Subject assess investigator unsuitable inclusion , instance , consider able understand comply study requirement , condition would allow safe participation study Male subject agree minimize risk female partner become pregnant first dose day two month study completion . Acceptable method contraception comprise barrier contraception medically accept contraceptive method female partner ( intrauterine device spermicide , hormonal contraceptive since least two month ) Evidence history macular degeneration abnormal find color discrimination test , clinically significant ophthalmic disorder base investigator 's discretion</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>